Skip to main content
Trials
Sponsors
Conditions
Drugs
Pricing
Trials
Sponsors
Conditions
Drugs
Pricing
Loading search results
Clinical Trials for "Lu"
441
trials
Share
Relevance
ID
Status
Phase
Title
Sponsor
NCT02649608
Completed
Phase 1
An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
H. Lundbeck A/S
ClinicalTrials.gov
NCT02649608
Completed
Phase 1
An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of...
H. Lundbeck A/S
NCT05724108
Active Not Recruiting
Phase 2
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
ClinicalTrials.gov
NCT05724108
Active Not Recruiting
Phase 2
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targe...
National Cancer Institute...
NCT07559175
Recruiting
Phase 2
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
Aimmune Nestle Health Science US R&D LLC
ClinicalTrials.gov · CTIS (EMA)
NCT07559175
Recruiting
Phase 2
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult P...
Aimmune Nestle Health Sci...
NCT04082325
Completed
Phase 1
Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men
H. Lundbeck A/S
ClinicalTrials.gov
NCT04082325
Completed
Phase 1
Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young M...
H. Lundbeck A/S
NCT02736448
Terminated
Phase 2
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
ClinicalTrials.gov
NCT02736448
Terminated
Phase 2
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine...
Istituto Romagnolo per lo...
NCT03394482
Completed
Phase 1
Bioequivalence Study of Lu AF35700
H. Lundbeck A/S
ClinicalTrials.gov
NCT03394482
Completed
Phase 1
Bioequivalence Study of Lu AF35700
H. Lundbeck A/S
NCT04199585
Terminated
Phase 1
Safety and Tolerability of Lu AF95245 in Healthy Young Men
H. Lundbeck A/S
ClinicalTrials.gov
NCT04199585
Terminated
Phase 1
Safety and Tolerability of Lu AF95245 in Healthy Young Men
H. Lundbeck A/S
NCT07661641
Recruiting
Phase 1
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors
Alpha-9 Oncology USA Inc.
ClinicalTrials.gov
NCT07661641
Recruiting
Phase 1
A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177...
Alpha-9 Oncology USA Inc.
NCT02388152
Terminated
Phase 1
Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease
H. Lundbeck A/S
ClinicalTrials.gov
NCT02388152
Terminated
Phase 1
Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in...
H. Lundbeck A/S
NCT07775261
Recruiting
Phase 1
A Trial of Lu AH69593 in Healthy Participants
H. Lundbeck A/S
ClinicalTrials.gov
NCT07775261
Recruiting
Phase 1
A Trial of Lu AH69593 in Healthy Participants
H. Lundbeck A/S
NCT06828263
Recruiting
Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer
Gustave Roussy, Cancer Campus, Grand Paris
ClinicalTrials.gov
NCT06828263
Recruiting
-
Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in M...
Gustave Roussy, Cancer Ca...
NCT01975779
Completed
Phase 1
Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects
H. Lundbeck A/S
ClinicalTrials.gov
NCT01975779
Completed
Phase 1
Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of...
H. Lundbeck A/S
NCT02093169
Completed
Phase 1
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
H. Lundbeck A/S
ClinicalTrials.gov
NCT02093169
Completed
Phase 1
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Us...
H. Lundbeck A/S
NCT04104503
Completed
Phase 1
A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects
H. Lundbeck A/S
ClinicalTrials.gov
NCT04104503
Completed
Phase 1
A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects
H. Lundbeck A/S
NCT04538014
Completed
Phase 1
A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain
H. Lundbeck A/S
ClinicalTrials.gov
NCT04538014
Completed
Phase 1
A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in t...
H. Lundbeck A/S
NCT04917484
Recruiting
Phase 2
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients
Tine Gregersen, MD
ClinicalTrials.gov
NCT04917484
Recruiting
Phase 2
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patien...
Tine Gregersen, MD
NCT05028673
Completed
Phase 1
A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants
H. Lundbeck A/S
ClinicalTrials.gov
NCT05028673
Completed
Phase 1
A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participan...
H. Lundbeck A/S
NCT06004180
Completed
Phase 1
A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)
H. Lundbeck A/S
ClinicalTrials.gov
NCT06004180
Completed
Phase 1
A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's...
H. Lundbeck A/S
NCT06077786
Completed
Phase 1
A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants
H. Lundbeck A/S
ClinicalTrials.gov · CTIS (EMA)
NCT06077786
Completed
Phase 1
A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adu...
H. Lundbeck A/S
NCT06546527
Not Yet Recruiting
Early Phase 1
Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）
Peking University First Hospital
ClinicalTrials.gov
NCT06546527
Not Yet Recruiting
Early Phase 1
Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCR...
Peking University First H...
Result Breakdown
Status
Completed
10 (50%)
Recruiting
5 (25%)
Terminated
3 (15%)
Active, not recruiting
1 (5%)
Not yet recruiting
1 (5%)
Phase
Phase 1
14 (70%)
Phase 2
4 (20%)
Not Specified
1 (5%)
Early Phase 1
1 (5%)
Top Conditions
Healthy
7 (35%)
Parkinson Disease
2 (10%)
Prostate Cancer
2 (10%)
Show 7 more
Top Sponsors
H. Lundbeck A/S
13 (65%)
National Cancer Institute (NCI)
1 (5%)
Aimmune Nestle Health Science US R&D LLC
1 (5%)
Show 7 more
Start your search
Search over 500,000 clinical trials worldwide
Search
Expert
Popular:
Cancer
Diabetes
Alzheimer
COVID-19
Heart Disease